The strategy of classical chiral switches of drugs isstill alive, contrary to a 2024 Journal of Medicinal ChemistryPerspective on approved chiral drugs claiming its death. Surveys ofapproved chiral-switch and racemic drugs should be based onreports of global regulatory authorities, not just FDA and EMA,which revealed overlooked chiral switches and racemates. Theapproved antihypertensive racemate nebivolol indicates thesynergy between its enantiomers, highlighting the advocacy ofdeveloping racemic drugs
The Death of the Strategy of Classical Chiral Switches Is an Exaggeration / Agranat, Israel; D'Acquarica, Ilaria. - In: ACS MEDICINAL CHEMISTRY LETTERS. - ISSN 1948-5875. - 15:11(2024), pp. 1797-1801. [10.1021/acsmedchemlett.4c00450]
The Death of the Strategy of Classical Chiral Switches Is an Exaggeration
D'Acquarica, Ilaria
Secondo
2024
Abstract
The strategy of classical chiral switches of drugs isstill alive, contrary to a 2024 Journal of Medicinal ChemistryPerspective on approved chiral drugs claiming its death. Surveys ofapproved chiral-switch and racemic drugs should be based onreports of global regulatory authorities, not just FDA and EMA,which revealed overlooked chiral switches and racemates. Theapproved antihypertensive racemate nebivolol indicates thesynergy between its enantiomers, highlighting the advocacy ofdeveloping racemic drugsI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
